Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
80
datasets available to search
ShareScore release 0.9.0
Dataset results
80 results for “Neuromyelitis Optica”
Immune repertoire profiling reveals its clinical application potential and triggers for Neuromyelitis Optica Spectrum Disorders
<p>This dataset, containing TCRbeta-chain sequcening data of Neuromyelitis Optica Spectrum Disorders patients and healthy, is the basis for the following publication: "Immune repertoire profiling reveals its clinical application potential and triggers for Neuromyelitis Optica Spectrum Disorders".</p>
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
ClinicalTrials.gov study NCT02200770. IPD Sharing: YES. Countries: 25. Publications: 9.
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
ClinicalTrials.gov study NCT01759602. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
ClinicalTrials.gov study NCT04660539. IPD Sharing: YES. Countries: 18. Publications: 1.
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
ClinicalTrials.gov study NCT00904826. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
ClinicalTrials.gov study NCT02028884. IPD Sharing: Not stated. Countries: 11. Publications: 5.
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
ClinicalTrials.gov study NCT02073279. IPD Sharing: Not stated. Countries: 15. Publications: 5.
Data from: Scrambler therapy improves pain in neuromyelitis optica: a randomized controlled trial
<p>Objective: The primary objective aimed to determine if Scrambler therapy is an effective, acceptable and feasible treatment of persistent central neuropathic pain in patients with neuromyelitis optica spectrum disorder (NMOSD). The secondary objective explored the effect of Scrambler therapy on co-occurring symptoms.</p> <p>Methods: We conducted a randomized single blind, sham-controlled trial in patients with NMOSD who have central neuropathic pain using Scrambler therapy for 10 consecutive weekdays. Pain severity, pain interference, anxiety, depression and sleep disturbance were assessed at baseline, end of treatment, and at 30- and 60-day follow-up.</p> <p>Results: Twenty-two patients (11 per arm) were enrolled into and completed this trial. The median baseline NRS pain score decreased from 5.0 to 1.5 following 10 days of treatment with Scrambler therapy, whereas the median NRS score did not significantly decrease in the sham arm. Depression was also reduced in the treatment arm, and anxiety was decreased in a subset of patients who responded to treatment. These symptoms were not impacted in the sham arm. The safety profiles were similar between groups.</p> <p>Conclusions: Scrambler therapy is an effective, feasible and safe intervention for central neuropathic pain in patients with NMOSD. Decreasing pain with Scrambler therapy may additionally improve depression and anxiety. Clinicaltrials.gov identifier NCT03452176 Classification of Evidence This study provides Class II evidence for patients with NMOSD and persistent central neuropathic pain that Scrambler therapy significantly reduces pain.</p>
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
ClinicalTrials.gov study NCT03819413. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
ClinicalTrials.gov study NCT04101058. IPD Sharing: UNDECIDED. Countries: 1. Publications: 17.
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
ClinicalTrials.gov study NCT01024985. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
ClinicalTrials.gov study NCT02850705. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
ClinicalTrials.gov study NCT03350633. IPD Sharing: NO. Countries: 1. Publications: 1.
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
ClinicalTrials.gov study NCT06620809. IPD Sharing: NO. Countries: 1. Publications: 2.
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
ClinicalTrials.gov study NCT02021825. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
ClinicalTrials.gov study NCT06865274. IPD Sharing: NO. Countries: 1. Publications: 30.
Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
ClinicalTrials.gov study NCT06763848. IPD Sharing: NO. Countries: 1. Publications: 6.
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
ClinicalTrials.gov study NCT00304291. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
ClinicalTrials.gov study NCT05314010. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
ClinicalTrials.gov study NCT04146285. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.